MX2015013036A - Composiciones promotoras. - Google Patents

Composiciones promotoras.

Info

Publication number
MX2015013036A
MX2015013036A MX2015013036A MX2015013036A MX2015013036A MX 2015013036 A MX2015013036 A MX 2015013036A MX 2015013036 A MX2015013036 A MX 2015013036A MX 2015013036 A MX2015013036 A MX 2015013036A MX 2015013036 A MX2015013036 A MX 2015013036A
Authority
MX
Mexico
Prior art keywords
seq
promoter compositions
promoter
compositions
nucleotides
Prior art date
Application number
MX2015013036A
Other languages
English (en)
Inventor
Beverly L Davidson
Edgardo Rodriguez
Alejandro Mas Monteys
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Publication of MX2015013036A publication Critical patent/MX2015013036A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describe una secuencia de promotor aislado que comprende un ácido nucleico con una longitud de entre 600 y 1700 nucleótidos teniendo al menos 90% de identidad de SEC ID NO:1, SEC ID NO:2, SEC ID NO:3, SEC ID NO:4, SEC ID NO:5, SEC ID NO:6, o SEC ID NO:7.
MX2015013036A 2013-03-15 2014-03-06 Composiciones promotoras. MX2015013036A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794818P 2013-03-15 2013-03-15
PCT/US2014/021357 WO2014149882A1 (en) 2013-03-15 2014-03-06 Promoter compositions

Publications (1)

Publication Number Publication Date
MX2015013036A true MX2015013036A (es) 2016-05-18

Family

ID=51580666

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013036A MX2015013036A (es) 2013-03-15 2014-03-06 Composiciones promotoras.

Country Status (15)

Country Link
US (1) US10105450B2 (es)
EP (1) EP2970969B1 (es)
JP (1) JP6473438B2 (es)
KR (1) KR102332835B1 (es)
CN (1) CN105358690B (es)
AU (1) AU2014237759B2 (es)
BR (1) BR112015022885A2 (es)
CA (1) CA2906315C (es)
ES (1) ES2809479T3 (es)
HK (1) HK1220486A1 (es)
IL (1) IL241667B (es)
MX (1) MX2015013036A (es)
RU (1) RU2742435C2 (es)
WO (1) WO2014149882A1 (es)
ZA (1) ZA201507439B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3404095B1 (en) 2012-05-02 2022-07-27 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US7205146B1 (en) * 2000-06-14 2007-04-17 Oscient Pharmaceuticals Corporation Nucleotide and amino acid sequences relating to respiratory diseases and obesity
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
JP2004008216A (ja) 2002-03-22 2004-01-15 Research Association For Biotechnology 新規な全長ｃＤＮＡ
JP2005237384A (ja) * 2002-03-22 2005-09-08 Research Association For Biotechnology 新規な全長ｃＤＮＡ
EP1707640A1 (en) * 2005-04-01 2006-10-04 Leiden University Medical Centre (LUMC) acting on behalf of the Academic Hospital Leiden Method of screening for the presence of a genetic defect associated with deep venous thrombosis
ITRM20050475A1 (it) * 2005-09-19 2007-03-20 Univ Degli Studi Genova Sequenze trascritte da rna polimerasi iii tipo iii e loro uso.
WO2007143037A2 (en) * 2006-05-31 2007-12-13 Orion Genomics Llc Gene methylation in cancer diagnosis
US20090018031A1 (en) 2006-12-07 2009-01-15 Switchgear Genomics Transcriptional regulatory elements of biological pathways tools, and methods
WO2008113773A2 (en) * 2007-03-16 2008-09-25 Biorigen S.R.L. Gene expression regulation technology and noncoding rnas for diagnosis and therapy
ES2334608B1 (es) * 2007-11-13 2011-01-24 Universidad Autonoma De Madrid Metodo para la identificacion de compuestos que inducen o inhiben estres de reticulo endoplasmatico o estres oxidativo.
EP3093351B1 (en) * 2008-07-09 2018-04-18 Celera Corporation Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
US8815779B2 (en) * 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods

Also Published As

Publication number Publication date
KR102332835B1 (ko) 2021-11-29
JP2016512028A (ja) 2016-04-25
AU2014237759B2 (en) 2020-02-27
RU2015144309A3 (es) 2018-03-13
EP2970969A1 (en) 2016-01-20
JP6473438B2 (ja) 2019-02-20
WO2014149882A1 (en) 2014-09-25
CA2906315A1 (en) 2014-09-25
CN105358690B (zh) 2019-12-31
KR20150129001A (ko) 2015-11-18
BR112015022885A2 (pt) 2017-11-07
EP2970969A4 (en) 2016-11-16
EP2970969B1 (en) 2020-05-06
US10105450B2 (en) 2018-10-23
RU2015144309A (ru) 2017-04-24
RU2742435C2 (ru) 2021-02-05
CN105358690A (zh) 2016-02-24
AU2014237759A1 (en) 2015-10-22
US20160022837A1 (en) 2016-01-28
CA2906315C (en) 2022-12-13
IL241667B (en) 2021-03-25
ZA201507439B (en) 2022-03-30
HK1220486A1 (zh) 2017-05-05
ES2809479T3 (es) 2021-03-04

Similar Documents

Publication Publication Date Title
AU2018200955B2 (en) Optimal maize loci
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
EP4303314A3 (en) Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
NZ631512A (en) Compositions and methods for modulating apolipoprotein (a) expression
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
MX2021009118A (es) Composiciones y metodos para inhibir la expresion del gen alas1.
MX2017008500A (es) Supresión del gen de la huntingtina inducida por la arni.
MX354267B (es) Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos.
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
MX2019006413A (es) Composiciones de arni de serpinc1 y metodos de uso de las mismas.
PH12014501726B1 (en) Glyphosate resistant plants and associated methods
IN2014MN02141A (es)
MX344972B (es) Oligonucleotidos inmunoestimulantes.
MX2018013216A (es) Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
IN2015MN00436A (es)
MX2021010716A (es) Composiciones y metodos para inhibir la expresion del gen lect2.
MX2022001017A (es) Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1).
MX2017008587A (es) Mirna natural para controlar la expresion de gen y uso del mismo.
MX2021013879A (es) Variantes de lipasa y polinucleotidos que las codifican.
MX2015013036A (es) Composiciones promotoras.
PH12017501859A1 (en) Plant promoter for transgene expression
IN2015DN02699A (es)
WO2014134403A3 (en) Aptamers that bind cd271
TW201614071A (en) Aptamer specific to colorectal cancer stem cell and application thereof

Legal Events

Date Code Title Description
FG Grant or registration